EZH2 is downstream of the pRB‐E2F pathway, essential for proliferation and amplified in cancer

By A. Bracken, Diego Pasini, M. Capra, Elena Prosperini, Elena Colli, K. Helin. EMBO Journal, 2003

1,238 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/921cfe566d7a1b9ba73eddec6f1b64fd7c821c36

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

Citations in the corpus

The role of mutations in epigenetic regulators in myeloid malignancies (2012, background): “While mutations in EZH1 or altered expression levels have not been found to date in human malignancies, overexpression of wildtype EZH2 is commonly seen in numerous epithelial diseases (66, 67).”
The Polycomb Ezh2 methyltransferase regulates muscle gene expression and skeletal muscle differentiation. (2004, background): “The latter effect is consistent with an antiproliferative effect exerted by either siRNA YY1 or siRNA Ezh2 (Bracken et al. 2003) on myoblasts (data not shown).”
A model for transmission of the H3K27me3 epigenetic mark (2008, background): “We have previously shown that the E2F transcription factors control expression of EZH2 , EED and SUZ12 , and that they are induced when cells are released from quiescence (G0) by mitogen stimulation and enter the S phase of the cell cycl”
Roles of the EZH2 histone methyltransferase in cancer epigenetics. (2008, background): “Similar requirements for EZH2 in roliferation of other cell types have been described [35,36].”
Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer (2007, background): “In a similar manner, de novo methylation may be triggered by an increase in PRC2 components, which is a common feature of many tumor”
Histone Modifications and Cancer. (2016, background): “EZH2 was among the earliest methyltransferase to have putative oncogenic capabilities because it was shown to be overexpressed or amplified in multiple cancers, including breast, prostate, and bladder (Bracken et al. 2003).”
SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells (2004, background): “One of the polycomb group genes EZH2 , is up-regulated in hormone-refractory, metastatic prostate cancer”
SUZ12 is required for both the histone methyltransferase activity and the silencing function of the EED-EZH2 complex. (2004, result): “…to our previous results using the native complex (Cao et al., 2002), the preferred the levels of EZH2 and SUZ12 and the invasiveness of these cancers (Bracken et al., 2003; Kirmizis et al., 2003; substrate for the reconstituted enzyme complex was histone H3 in oligonucleosome form (Figure 1D).”